Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
September 07, 2017 16:05 ET
|
Kura Oncology, Inc.
Four of the first six HRAS mutant HNSCC patients enrolled on study achieve confirmed RECIST partial responses Durable responses greater than one year observed SAN DIEGO, Sept. 07, 2017 (GLOBE...
Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference
August 29, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of Public Offering of Common Stock
August 10, 2017 22:11 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study
August 07, 2017 16:05 ET
|
Kura Oncology, Inc.
Tipifarnib demonstrates high level of clinical activity and durable partial responses in ongoing Phase 2 trial in HRAS mutant squamous cell head and neck cancers Management to host webcast and...
Kura Oncology to Report Second Quarter 2017 Financial Results
July 31, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck Cancer
July 18, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck Cancer
July 13, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Added to Russell 3000® Index
June 26, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
June 14, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
June 07, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...